Drug intelligence / Profile preview

SVV-024

Development stage: Preclinical
Lead developer: Seneca Therapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

SVV-024 is an investigational **armed oncolytic virus immunotherapy** being developed by Seneca Therapeutics for cancer. It is a **Seneca Valley Virus based gene therapy construct** designed to selectively infect **TEM8 expressing tumor cells**, while sparing normal cells that reportedly lack meaningful TEM8 expression. The construct carries an **enhanced interleukin-2 transgene** intended to stimulate anti-tumor immunity by engaging IL-2 receptor signaling in tumors without activating **CD25**, with the goal of avoiding toxicities associated with recombinant IL-2 protein therapy. Overall, SVV-024 is best described as a tumor-selective oncolytic viral immunotherapy and cytokine gene-delivery program in preclinical or early development.

Other names: SVV+ Enhanced IL-2 Gene

Targets

ANTXR1 (Anthrax toxin receptor 1)IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on SVV-024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVV-024.

Explore the full profile